Ipsen shares drop 3% after pulling Tazverik over blood cancer risk

Investing.com Gold reports: Ipsen shares drop 3% after pulling Tazverik over blood cancer risk. This is a premium/paywalled source, so the brief is based on headline and available metadata only.